Skip to main
ARTL

ARTL Stock Forecast & Price Target

ARTL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artelo Biosciences Inc is focusing on the development of therapeutics aimed at the endocannabinoid system, with early clinical data demonstrating improvements in biomarkers related to muscle mass and weight maintenance, indicating significant potential clinical benefits. The company's flagship program is attributed to compelling scientific foundations and addresses a substantial market opportunity in treating rare and orphan diseases, particularly concerning cachexia. With upcoming clinical readouts expected to drive value inflection, Artelo Biosciences's approach appears fundamentally promising for both investors and the advancement of cannabis-based therapies.

Bears say

Artelo Biosciences Inc faces a negative outlook primarily due to a recent $3 million capital raise, which raises concerns about potential dilution and introduces near-term uncertainty for investors. The situation is exacerbated by the company's confusing strategic direction and poor communication, leading to a lack of clarity regarding its future path and operational focus. This combination of factors creates a cycle of downward pressure on the company's valuation, particularly as additional fundraising may be necessary before achieving key clinical milestones.

ARTL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artelo Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artelo Biosciences Inc (ARTL) Forecast

Analysts have given ARTL a Strong Buy based on their latest research and market trends.

According to 2 analysts, ARTL has a Strong Buy consensus rating as of Jan 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artelo Biosciences Inc (ARTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.